BRAF and neoplasm: Thirty-six tumor samples from 19 BRAF V600+ and 17 BRAF V600− patients (three of whom had pathogenetic mutations in the KIT gene) were analyzed and their mutational profiles/CNV/LOH correlated with clinical response.